India's Pharma Future: Revolutionizing Healthcare Access
Access to new-age medicines for obesity and diabetes is crucial for the Indian pharmaceutical industry's growth. Combined with AI tools, this will support accessibility and affordability. India aims to transform into a global pharmaceutical innovation hub, targeting a USD 500 billion industry by 2047.
- Country:
- India
The Indian pharmaceutical industry is poised for transformation as access to new medicines for obesity and diabetes becomes a pivotal growth factor, according to Kirti Ganorkar, Managing Director of Sun Pharma.
Glucagon-like peptide-1 (GLP-1) receptor agonists, essential drugs for treating type 2 diabetes and obesity, will drive industry growth, especially as India emerges as a global weight management hub amid rising obesity-related diseases.
AI-driven tools, personalized medicine, and increased risk capital will fuel innovation, making India a recognized pharmaceutical innovation center by 2026. This aligns with India's vision of a USD 500 billion industry by 2047, overcoming global healthcare challenges and advancing scientific and regulatory excellence.
ALSO READ
-
Japanese Lawmakers Visit India to See Worker Protection and Skills Projects in Action
-
Indian Unions Push for Fair Recruitment and Rights for Care Workers in Germany
-
Cleaner Kitchens, Polluted Skies: Hidden Health Cost of India’s Electricity Boom
-
Japan-Backed ILO Projects Help 23,000 Workers Gain Rights and Fight Child Labour
-
India's Delicate Balancing Act: Navigating Energy Security Amid Middle Eastern Tensions
Google News